Radiation damages the DNA in the cell nucleus, thereby inducing cell death. In cancer treatment there is an important need for targeted therapies that selectively kill residual and metastatic cancer cells, that escaped from conventional treatment options. Targeted radionuclide therapy (TRNT) is based on the specific delivery of cytotoxic radiation to cancer cells. Essential for efficient TRNT is the use of (1) vehicles that can deliver these radionuclides specifically to cancer cells and (2) radionuclides that are able to deliver a lot of energy within their close surrounding. The “theranostic” approach aims to integrate the diagnostic testing for the presence of a molecular target into TRNT, where it allows the prediction of successful TRNT and therefore improves treatment. Additional advantages are the improved prediction of the dose needed to treat, and the ability to monitor therapy responses. Nanobodies (nbs) could give a solution to the limitations of today’s clinically applied TRNT. These antigen-binding fragments, derived from heavy-chain-antibodies of camelidae, are the smallest antibody-derived fragments and have superior characteristics compared to classical mAbs and their derived fragments. The aim of the current proposal focuses on the optimization and validation of a generic nb-based theranostic platform for the treatment of cancer. Moreover, it will address several fundamental questions, essential for the clinical translation of nb-based theranostics.
Effective start/end date1/10/1530/09/21

    Research areas

  • cancer therapy

    Flemish discipline codes

  • Diagnostic radiology

ID: 26490899